{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:40:30Z","timestamp":1792795230055,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ekir.2024.10.007","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T21:18:29Z","timestamp":1729027109000},"page":"145-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Systematic Review of Safety and Efficacy of Factor XI\/XIa Inhibitors in Patients With ESKD on Hemodialysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Daniel","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kraemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Nopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"K\u00f6nigsbr\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.10.007_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.10.007_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2024.10.007_bib4","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.007_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish atrial fibrillation Cohort study","volume":"36","author":"Friberg","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2024.10.007_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1523-1755.2003.00101.x","article-title":"Elevated risk of stroke among patients with end-stage renal disease","volume":"64","author":"Seliger","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.10.007_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/ki.1993.352","article-title":"Evidence for high risk of cerebral hemorrhage in chronic dialysis patients","volume":"44","author":"Iseki","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.10.007_bib9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/rth2.12250","article-title":"Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation","volume":"3","author":"K\u00f6nigsbr\u00fcgge","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamainternmed.2015.6102","article-title":"Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review","volume":"176","author":"Konstantinidis","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review","volume":"7","author":"Colombijn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2024.10.007_bib12","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.007_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing Apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.007_bib14","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and Efficacy of vitamin K antagonists versus Rivaroxaban in hemodialysis Patients with atrial fibrillation: a Multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.007_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102332","article-title":"Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists","volume":"8","author":"Tscharre","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib16","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/jth.15508","article-title":"Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: from the VIVALDI, a population-based prospective cohort study","volume":"19","author":"K\u00f6nigsbr\u00fcgge","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvae002","article-title":"Pharmacological and clinical appraisal of factor XI inhibitor drugs","volume":"10","author":"Occhipinti","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ekir.2024.10.007_bib18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.007_bib19","first-page":"049","article-title":"Reshaping anticoagulation: factor XI inhibition in thrombosis management","volume":"44","author":"Verstraete","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ekir.2024.10.007_bib20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.10.007_bib21","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.10.007_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.ekir.2024.10.007_bib24","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (factor XI) levels and risk of stroke","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.ekir.2024.10.007_bib25","article-title":"Genetically proxied inhibition of coagulation factors and risk of cardiovascular disease: a Mendelian randomization study","volume":"10","author":"Yuan","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2024.10.007_bib26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2516.2008.01667.x","article-title":"Factor XI deficiency","volume":"14","author":"GOMEZ","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.ekir.2024.10.007_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/hae.12628","article-title":"Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre","volume":"21","author":"Santoro","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.ekir.2024.10.007_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2024.10.007_bib31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib32","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib34","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery\u2014systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib35","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib36","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.10.007_bib37","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2024.10.007_bib38","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 4:. Searching for and selecting studies","author":"Lefebvre","year":"2023"},{"key":"10.1016\/j.ekir.2024.10.007_bib39","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2024.10.007_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J\u00a0Educ Behav Stat"},{"key":"10.1016\/j.ekir.2024.10.007_bib42","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.ekir.2024.10.007_bib43","first-page":"1","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.ekir.2024.10.007_bib44","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.10.007_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.10.007_bib46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2024.10.007_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A\u00a0Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.10.007_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ekir.2024.10.007_bib50","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/ndt\/12.11.2355","article-title":"Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation","volume":"12","author":"Amb\u00fchl","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.10.007_bib51","first-page":"874","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.10.007_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.10.007_bib53","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","article-title":"Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion","volume":"37","author":"De Vriese","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.10.007_bib54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2020.05.010","article-title":"A\u00a0comparison of the risk of acute myocardial infarction in patients receiving hemodialysis and peritoneal dialysis: a population-based, propensity score-matched cohort study","volume":"307","author":"Sun","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ekir.2024.10.007_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12509","article-title":"Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition","volume":"5","author":"Mavromanoli","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib56","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A\u00a0role for factor XIIa-mediated factor XI activation in thrombus formation in\u00a0vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.10.007_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a Phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ekir.2024.10.007_bib58","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.ekir.2024.10.007_bib59","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2024.10.007_bib60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.10.007_bib61","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A\u00a0multicenter, Phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral Factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2024.10.007_bib62","author":"Ruff"},{"key":"10.1016\/j.ekir.2024.10.007_bib63","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.10.007_bib64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ekir.2024.10.007_bib65","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","author":"Piccini","year":"2024","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492401965X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492401965X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:11:52Z","timestamp":1734927112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492401965X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S246802492401965X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.10.007","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Safety and Efficacy of Factor XI\/XIa Inhibitors in Patients With ESKD on Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.10.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}